N2N Technologies Limited is an Indian IT services provider listed on the **BSE (Scrip Code: 512279)**. Historically focused on **Information Technology (IT)** and **IT Enabled Services (ITeS)**, the company is currently at a critical strategic inflection point. As of **late 2025**, the organization is transitioning from a small-cap IT service provider into a healthcare-oriented entity under new leadership. --- ### **Strategic Pivot: The 2025 Change in Control** The company is undergoing a fundamental transformation following a mandatory open offer and an **Acquisition of Control Agreement (ACA)** triggered in **November 2025**. * **The Acquirer:** **Harmony Remedies India Private Limited**, a wholesale distributor of healthcare and pharmaceutical products, is assuming management and operational control. * **Exit of Existing Promoter:** The current promoter, **Mr. Rahul Shah**, is transitioning out of his leadership role due to an inability to devote sufficient time to the business. * **Joint Promoter Status:** Upon completion of the transaction, the Acquirer will be classified as a **joint promoter**. * **Sector Shift:** The primary long-term objective of the new management is to **diversify into the pharmaceutical sector**. The Acquirer intends to eventually discontinue the legacy IT business in favor of pharma operations and potential restructuring to leverage synergies with Harmony Remedies' existing business. **Open Offer Details:** | Feature | Details | | :--- | :--- | | **Offer Size** | Up to **1,291,228 Equity Shares** (**40.00%** of Voting Capital) | | **Offer Price** | **₹ 4.30** per fully paid-up equity share | | **Total Consideration** | Up to **₹ 55,52,280.40** | | **Escrow Status** | **>100%** of consideration deposited in cash | | **Regulatory Trigger** | **Regulations 3(1) and 4** of SEBI (SAST) Regulations, 2011 | --- ### **Legacy IT Operations & Market Position** Until the full execution of the pharmaceutical pivot, the company continues to operate as a single-segment entity in the IT space. * **Core Services:** Provision of **IT Professional Services** and **Tech Support Services**, with a specific operational focus on serving **Consello Technologies Inc. USA**. * **Market Challenges:** The company faces intense pressure from the **institutionalization** of the IT industry, where large-scale players dominate. * **Geographic Exposure:** Revenue is heavily dependent on the **USA IT market**, which is currently characterized by volatility and downward pressure. * **Operational Scale:** The company’s small-to-mid-cap size has limited its ability to penetrate broader markets, leading to a "partially positive" outlook for its traditional business lines. --- ### **Financial Performance & Capital Structure** N2N Technologies has struggled with inconsistent revenue and persistent net losses, leading to a suspension of dividends to protect stakeholder interests. **Standalone Financial Highlights (₹ Lakhs):** | Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | | :--- | :--- | :--- | :--- | :--- | | **Total Income** | **141.12** | **161.43** | **61.33** | **Nil** | | **Total Expenditure** | **168.02** | **164.91** | **59.78** | **6.11** | | **Profit / (Loss) Before Tax** | **(26.89)** | **(3.47)** | **1.55** | **(465.42)** | **Capital and Shareholding (as of March 31, 2025):** * **Total Paid-up Share Capital:** **₹ 4,01,31,980** * **Equity Shares:** **32,28,069** shares (Face Value **₹ 10**) * **Promoter Holding:** **43.11%** (held by Mr. Rahul Shah) * **Preference Shares:** **7,85,129** shares. Due to insufficient cash flows, the redemption date for these shares has been extended by a decade, from **March 28, 2027**, to **March 28, 2037**. --- ### **Regulatory, Compliance & Governance Risks** The company faces a complex landscape of regulatory friction and internal control deficiencies that the new management must address. * **BSE Listing Status:** Trading is currently **suspended** due to non-payment of **Annual Listing Fees** for three consecutive fiscal years (**FY24–FY26**). An application for revocation was filed on **October 24, 2025**. * **SEBI Restrictions:** The current promoter, **Rahul Shah**, is under a **six-month restraint** (issued August 29, 2025) from dealing in the securities market. * **Governance Lapses:** The company is currently in violation of the **Companies Act, 2013** and **SEBI LODR** for failing to appoint an **Independent Director**, resulting in improperly constituted Board Committees. * **Audit Qualifications:** Auditors have issued **Qualified Opinions** regarding: * Lack of an **audit trail (edit log)** in accounting software. * Failure to appoint an **Internal Auditor**. * Absence of third-party **balance confirmations** for trade payables and receivables. * **Section 186 Violations:** Outstanding loans of **₹ 6.17 Crore** exceed the permissible limit of **₹ 4.14 Crore** without the required shareholder resolutions. --- ### **Taxation & Statutory Liabilities** The company carries significant financial baggage in the form of unpaid taxes and penalties. * **Income Tax Demands:** Total outstanding demands exceed **₹ 1.99 Crore**, with the largest chunk (**₹ 1.14 Crore**) dating back to **A.Y. 2014-15**. * **GST & TDS Issues:** A delay in GST registration resulted in **₹ 1.12 Crore** of unreported turnover and a loss of **Input Tax Credit**. Furthermore, **TDS** on professional fees and rent has remained unpaid for over **three years**. * **Stamp Duty:** Unpaid stamp duty remains an issue regarding the historical merger of **Leadsoft Softech Pvt Ltd**. --- ### **Forward-Looking Recovery Plan** The Acquirer, **Harmony Remedies**, has outlined a roadmap to stabilize the entity: 1. **Revocation of Suspension:** Prioritizing the restoration of trading on the BSE. 2. **Board Reconstitution:** Appointing new nominees and Independent Directors to meet statutory requirements. 3. **MPS Compliance:** Committing to achieving the **25% Minimum Public Shareholding** within **12 months** if the open offer reduces the public float below that level. 4. **Operational Continuity:** Maintaining existing IT contracts in the short term while preparing the infrastructure for a **pharmaceutical sector pivot**.